Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT05482074
Phase
PHASE2
Status
Withdrawn

Conditions

  • Cutaneous Melanoma
  • Mucosal Melanoma
  • Recurrent Metastatic Melanoma
  • Uveal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Oral, twice a day, dosage per protocol, per 28 day cycle

Study Details

The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy. -The name of the study drug involved in this study is: Olaparib (also known as Lynparza)

Key Dates

Start date
Oct 4, 2022
Status verified
Jan 2024
Primary completion
May 1, 2026
Completion
May 1, 2027

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: OLAPARIB
    The research study procedures include screening for eligibility, study treatment including evaluations, surveys, optional biopsies, and follow up visits Olaparib- Each study treatment cycle lasts 28 days . This will continue for as long as the study treatment is providing clinical benefit

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 12 weeks ]

Related Studies